Home › Funds › Bellevue Group AG › RARE
Bellevue Group AG position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
Bellevue Group AG reported holding 1,982,775 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$66.2M, representing 1.39% of its reported portfolio and ranking #27 among its reported holdings. Bellevue Group AG has disclosed RARE holdings in 6 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's RARE position evolved
Bellevue Group AG first disclosed a stake in RARE in Q2 2024 at 4,000 shares (US$164K). The position peaked in Q2 2026 at 1,982,775 shares, worth US$66.2M. Across 6 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,982,775 shares valued at US$66.2M — a reduction of -397,225 shares quarter over quarter.. Notable position changes include a 92148% increase in Q1 2026 (shares rose 59% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 4.00K | $164.40K | New |
| Q3 2024 | 4.00K | $222.20K | Hold |
| Q4 2024 | 4.00K | $168.28K | Hold |
| Q4 2025 | 2.58K | $59.34K | New |
| Q1 2026 | 2.38M | $49.86M | Add |
| Q2 2026 | 1.98M | $66.20M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 26 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 7.80M sh · $260.34M · Q2 2026
- SANDS CAPITAL MANAGEMENT, LLC 3.16M sh · $105.46M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held RARE?
Bellevue Group AG has disclosed RARE holdings in 6 of the last 9 reported quarters, going back to Q2 2024.
What is Bellevue Group AG's current position in RARE?
As of Q2 2026, Bellevue Group AG holds 1.98M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $66.20M, representing 1.39% of its reported portfolio and ranking #27.
Has Bellevue Group AG been buying or selling RARE?
In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in RARE. The position peaked in Q2 2026 at 1.98M shares.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, FRONTIER CAPITAL MANAGEMENT CO LLC, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.